Delivery Order SPE2DB22D3501-SPE2DB25FXK65
- Not listed
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $41,480.40 to AmerisourceBergen Drug Corp on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award carries no set-aside designation...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $14,140.36 to AmerisourceBergen Drug Corp on September 1, 2025, with an ultimate completion date of September 2, 2025. This firm fixed-price delivery order, issued under a competitive, non-set-aside procurement, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026....
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $4,083.60 to AmerisourceBergen Drug Corp on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The award was competitively granted with no set-aside designation, reflecting the...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for a firm fixed price of approximately $52.6K. This non-competed delivery order, issued under contract number 4568976012, represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $1.0 billion through December 2026. The award is designated for performance at AmerisourceBergen's corporate...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $87,321.50 to AmerisourceBergen Drug Corp on August 25, 2025, with completion expected by August 26, 2025. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The delivery order will be performed at AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a $1,746.48 delivery order to AmerisourceBergen Drug Corp on April 29, 2025, with completion targeted for April 30, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The contract supports federal pharmaceutical and medical supply...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $56,394.30 to AmerisourceBergen Drug Corp on September 1, 2025, with an ultimate completion date of September 2, 2025. This firm fixed-price delivery order, issued under a non-set-aside competitive procurement, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The work will be...
- The U.S. Defense Logistics Agency (DLA), through its Medical Supply Chain division, awarded a delivery order valued at $16,589.43 to AmerisourceBergen Drug Corp on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $21,395.95 to AmerisourceBergen Drug Corp on September 6, 2025, with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending through December 2026. The delivery order represents a...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $1,646.74 to AmerisourceBergen Drug Corp on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The work will be performed at AmerisourceBergen's corporate office...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXK65Delivery Order
The Defense Logistics Agency (DLA) awarded a $5,619.47 delivery order to AmerisourceBergen Drug Corp for AKOVAZ 50 mg/mL vials, with performance in Conshohocken, Pennsylvania and completion by September 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This delivery order aligns with AmerisourceBergen's established role as a prime vendor within the DLA Medical Supply Chain, fulfilling the Defense Health Agency's pharmaceutical needs. The company's contract award portfolio demonstrates consistent capability in delivering diverse medical commodities, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. The $1 billion IDC serves as a flexible vehicle enabling AmerisourceBergen to respond to variable federal medical supply requirements, supporting military healthcare systems and other government health agencies worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 9/18/25 |